Compounds > ipamorelin
Page last updated: 2024-12-11

ipamorelin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9831659
CHEMBL ID58547
SCHEMBL ID183305
SCHEMBL ID8169698
MeSH IDM0295513

Synonyms (23)

Synonym
ipamorelin [inn]
aib-his-2nal-phe-lys-nh2
170851-70-4
y9m3s784z6 ,
unii-y9m3s784z6
2-methylalanyl-l-histidyl-3-(2-naphthyl)-d-alanyl-d-phenylalanyl-l-lysinamide.
2-methylalanyl-l-histidyl-3-(2-naphthyl)-d-alanyl-d-phenylalanyl-l-lysinamide
ipamorelin ,
NCGC00167295-01
nnc-26-0161
aib-his-d-2-nal-d-phe-lys-nh2
nnc-260161
CHEMBL58547
nnc 26-0161
ipamorelin [who-dd]
SCHEMBL183305
SCHEMBL8169698
AKOS030573449
DB12370
AMY25371
ipamorelin acetate
AS-56185
VGA85170

Research Excerpts

Overview

Ipamorelin is a new and potent synthetic pentapeptide. It has distinct and specific growth hormone (GH)-releasing properties.

ExcerptReferenceRelevance
"Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2), which displays high GH releasing potency and efficacy in vitro and in vivo."( Ipamorelin, the first selective growth hormone secretagogue.
Andersen, PH; Ankersen, M; Hansen, BS; Johansen, NL; Madsen, K; Raun, K; Thøgersen, H, 1998)		2.46
"Ipamorelin is a new and potent synthetic pentapeptide which has distinct and specific growth hormone (GH)-releasing properties. "( Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.
Andreassen, TT; Flyvbjerg, A; Johansen, PB; Nowak, J; Orskov, H; Skjaerbaek, C; Wilken, M, 1999)		3.19

Bioavailability

NNC 26-0235 and ipamorelin were able to increase basal GH level by more than 10-fold after oral administration of a dose of 1.

ExcerptReferenceRelevance
" After intranasal application, the bioavailability of ipamorelin was estimated at approximately 20%."( Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption.
Andersen, JV; Hansen, KT; Johansen, NL; Johansen, PB, 1998)		0.84

Dosage Studied

ExcerptRelevanceReference
" In vivo potency in swine after iv dosing is reported, and ED50 was found to be 30 nmol/kg of body weight for the most potent compound."( Novel orally active growth hormone secretagogues.
Andersen, PH; Ankersen, M; Hansen, BS; Hansen, TK; Johansen, NL; Lau, J; Lundt, BF; Madsen, K; Nielsen, KK; Peschke, B; Raun, K; Thøgersen, H, 1998)		0.3
"01-1 mg/kg), growth hormone-releasing peptide (GHRP)-6 (20 microg/kg), or vehicle (saline) were administered via intravenous bolus infusion after a single dosing or a 2-day repetitive dosing regimen (four doses a day at 3-h intervals)."( Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.
Greenwood-Van Meerveld, B; Mann, W; Nelson, R; Venkova, K, 2009)		0.73
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency0.79435.623417.292931.6228AID485281
alpha-galactosidaseHomo sapiens (human)Potency0.79434.466818.391635.4813AID2107
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.07080.010039.53711,122.0200AID1479
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID209311Compound was tested for potency against GH release iv administration in swine1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Novel orally active growth hormone secretagogues.
AID61090Basal GH release was measured after 0.5 mg/kg iv administration into Beagle dogs1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.
AID176149Tested in vivo for GH-releasing potency against anesthetized male rats1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.
AID10685Area under curve was measured after i.v. administration into Beagle dog.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.
AID18437Oral bioavailability in dog (Beagle)1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.
AID159530Release of growth hormone at single iv dose of 50 nmol/kg in pigs2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin.
AID195921Tested in vitro for GH-releasing potency against rat pituitary cells.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.
AID13883Maximum Concentration was measured after po administration into Beagle dog.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.
AID159423Effective dose required for release of GH from pigs in vivo2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin.
AID195930Efficacy was determined as percent of GHRP-6 in rat pituitary cell assay tested in vitro2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin.
AID209314Compound was tested for efficacy against GH release iv administration in swine1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Novel orally active growth hormone secretagogues.
AID61092Basal GH release was measured after 2.7 mg/kg po administration into Beagle dogs1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.
AID13881Maximum Concentration was measured after iv administration into Beagle dog.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.
AID10688Area under curve was measured after po administration into Beagle dog.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.
AID195923Concentration required for GH release from isolated pituitary cells of rat tested in vitro2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin.
AID209313Compound was tested for GH-releasing potency against female Danish slaughter swine.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.
AID209310Compound was tested for GH-releasing potency against female Danish slaughter swine.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.
AID179870Tested in vivo for GH-releasing potency against anesthetized male rats1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.
AID195929Tested in vitro for GH-releasing potency against rat pituitary cells.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (26.92)18.2507
2000's13 (50.00)29.6817
2010's6 (23.08)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 77.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index77.64 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index148.51 (26.88)
Search Engine Supply Index2.25 (0.95)

This Compound (77.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (7.41%)5.53%
Reviews2 (7.41%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (85.19%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
glycine
[no description available]		2.4620alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
propranolol
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.		2.0210naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
serine
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.		210L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
phenylalanine
Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.		210amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
methylprednisolone
Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.		2.41206-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic
yohimbine
Yohimbine: A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of ERECTILE DYSFUNCTION.. yohimbine : An indole alkaloid with alpha2-adrenoceptor antagonist activity. It is produced by Corynanthe johimbe and Rauwolfia serpentina.		2.0210methyl 17-hydroxy-20xi-yohimban-16-carboxylatealpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist
l 692429
L 692429: stimulates release of growth hormone; RN refers to (R)-isomer; structure given in first source		3.1210
tyrosyl-tryptophyl-alanyl-tryptophyl-phenylalaninamide
tyrosyl-tryptophyl-alanyl-tryptophyl-phenylalaninamide: RN given refers to (L-Tyr-D-Trp-L-Ala-D-Trp-L-Phe-NH2)-isomer		2.1110
l 163191
[no description available]		210
deamino arginine vasopressin
Deamino Arginine Vasopressin: A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR.		2.1110heterodetic cyclic peptidediagnostic agent;
renal agent;
vasopressin receptor agonist
boron
Boron: A trace element with the atomic symbol B, atomic number 5, and atomic weight [10.806; 10.821]. Boron-10, an isotope of boron, is used as a neutron absorber in BORON NEUTRON CAPTURE THERAPY.		2.1710boron group element atom;
metalloid atom;
nonmetal atom		micronutrient
ibutamoren mesylate
ibutamoren mesylate: a growth hormone secretagogue; structure in first source		4.3130
hexarelin
hexarelin: a synthetic growth hormone releasing peptide; structurally similar to GHRP-6, with the substitution of D-Trp with its 2-methyl derivative; more potent & stable and less toxic than GHRP-6		9.140
sm 130686
SM 130686: a growth hormone secretagogue; structure in first source		3.1210
tabimorelin
tabimorelin: a growth hormone secretagogue; structure in first source		4.0240
sk&f 110679
[no description available]		2.420
ghrp-1
alanyl-histidyl-(2-naphthyl)alanyl-tryptophyl-phenylalanyl-lysinamide: amino acid sequence given in first source; a second generation growth hormone-releasing peptide		7.8130
piperidines
Piperidines: A family of hexahydropyridines.		2.0210
ConditionIndicatedRelationship StrengthStudiesTrials
Complication, Postoperative
[description not available]		07.6954
Emesis
[description not available]		07.5244
Nausea
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.		07.5244
Postoperative Complications
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.		07.6954
Vomiting
The forcible expulsion of the contents of the STOMACH through the MOUTH.		07.5244
Ileus
A condition caused by the lack of intestinal PERISTALSIS or INTESTINAL MOTILITY without any mechanical obstruction. This interference of the flow of INTESTINAL CONTENTS often leads to INTESTINAL OBSTRUCTION. Ileus may be classified into postoperative, inflammatory, metabolic, neurogenic, and drug-induced.		110.7564
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		03.2660
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0510
Appetite Disorders
[description not available]		02.9310
Dwarfism, Growth Hormone Deficiency
[description not available]		02.9310
Long Sleeper Syndrome
[description not available]		02.9310
Feeding and Eating Disorders
A group of disorders characterized by physiological and psychological disturbances in appetite or food intake.		02.9310
Dwarfism, Pituitary
A form of dwarfism caused by complete or partial GROWTH HORMONE deficiency, resulting from either the lack of GROWTH HORMONE-RELEASING FACTOR from the HYPOTHALAMUS or from the mutations in the growth hormone gene (GH1) in the PITUITARY GLAND. It is also known as Type I pituitary dwarfism. Human hypophysial dwarf is caused by a deficiency of HUMAN GROWTH HORMONE during development.		02.9310
Sleep Wake Disorders
Abnormal sleep-wake schedule or pattern associated with the CIRCADIAN RHYTHM which affect the length, timing, and/or rigidity of the sleep-wake cycle relative to the day-night cycle.		02.9310
Alloxan Diabetes
[description not available]		02.0210
Anesthesia
A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.		01.9910
Weight Gain
Increase in BODY WEIGHT over existing weight.		0210
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		0210